



October 18, 2017

Innoviva to Report Third Quarter Financial Results on October 25 at 5:00 p.m. EDT

BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m. EDT/2:00 p.m. PDT to discuss the financial results and provide a corporate update.

To participate in the live call, dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers, and enter Conference ID: 2272916. A live webcast of the call will be available at: <https://edge.media-server.com/m6/p/abjk7qxo> or from the investor relations section of the company website at www.inva.com and will be archived for 30 days. A telephone replay of the call will be available for seven days, through November 1, by dialing (404) 537-3406.

About Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc., including the closed triple combination therapy for Chronic Obstructive Pulmonary Disease (COPD). For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20171018005053/en/>

Innoviva, Inc.
Eric d'Esparbes
Senior Vice President and Chief Financial Officer
650-238-9640
investor.relations@inva.com

Source: Innoviva

News Provided by Acquire Media